See Important Reminder at the end of this policy for important regulatory and legal information.

Transcription

1 Clinical Policy: (Herceptin) Reference Number: ERX.SPA.42 Effective Date: Last Review Date: 05/17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description (Herceptin ) is a human epidermal growth factor receptor 2 protein (HER2)/neu receptor antagonist. FDA approved indication Herceptin is indicated: For the adjuvant treatment of HER2-overexpressing node positive or node negative (ER/PR negative or with one high risk feature) breast cancer: o As part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel o With docetaxel and carboplatin o As a single agent following multi-modality anthracycline based therapy For the treatment of HER2-overexpressing metastatic breast cancer: o In combination with paclitaxel for first-line treatment o As a single agent in patients who have received one or more chemotherapy regimens for metastatic disease For the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma in combination with cisplatin and capecitabine or 5-fluorouracil for the treatment of patients who have not received prior treatment for metastatic disease Policy/Criteria Provider must submit documentation (including office chart notes and lab results) supporting that member has met all approval criteria It is the policy of health plans affiliated with Envolve Pharmacy Solutions that Herceptin is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Non-Metastatic Breast Cancer (must meet all): 1. Diagnosis of human epidermal growth factor receptor 2 protein (HER-2) positive nonmetastatic breast cancer; 2. Will be used for one of the following indications (a or b): a. FDA approved use (i and ii): i. One of the following disease characteristics (a or b): a) Node positive disease; b) Node negative disease with one or more of the following risk factors: 1) Estrogen receptor (ER)/progesterone receptor (PR) negative; 2) Pathological tumor size > 2 cm; 3) Histologic and/or nuclear grade 2 or 3; 4) Age < 35 years; Will be used as adjuvant treatment in one of the following ways (a, b, or c): a) As part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; b) With docetaxel and carboplatin; c) As a single agent following multi-modality anthracycline-based therapy; Page 1 of 5

2 b. Off-label NCCN recommended use (i, ii, or iii): i. Herceptin will be used for preoperative systemic therapy in one of the following ways (a, b, c, d, or e): a) In combination with paclitaxel following AC (doxorubicin and cyclophosphamide) regimen as preferred regimen with or without pertuzumab; b) In TCH (docetaxel, carboplatin, and trastuzumab) regimen with or without pertuzumab as preferred regimen; c) In combination with docetaxel with or without pertuzumab following AC regimen; d) In combination with docetaxel and cyclophosphamide; e) In combination with pertuzumab and paclitaxel or pertuzumab and docetaxel prior to or following FEC/CEF (fluorouracil, epirubicin, and cyclophosphamide) regimen; Herceptin will be used as adjuvant systemic therapy in one of the following ways (a, b, c, d, e, f, or g): a) In combination with paclitaxel following AC (doxorubicin and cyclophosphamide) regimen as preferred regimen; b) In TCH (docetaxel, carboplatin, and trastuzumab) regimen as preferred regimen; c) In combination with docetaxel following AC regimen; d) In combination with docetaxel and cyclophosphamide; e) In TCH regimen (as preferred regimen) with pertuzumab if a pertuzumabcontaining regimen was not used as neoadjuvant therapy; f) In combination with pertuzumab and paclitaxel (as preferred regimen) or pertuzumab and docetaxel following AC regimen if a pertuzumab-containing regimen was not used as neoadjuvant therapy; g) In combination with pertuzumab and either paclitaxel or docetaxel prior to or following FEC/CEF (fluorouracil, epirubicin, and cyclophosphamide) regimen if a pertuzumab-containing regimen was not used as neoadjuvant therapy; i In combination with paclitaxel for low-risk stage I, HER2-positive disease particularly for members not eligible for other standard adjuvant regimens due to comorbidities. B. Metastatic and Recurrent Breast Cancer (must meet all): 1. Diagnosis of recurrent or metastatic HER2-positive breast cancer; 2. Will be used for one of the following indications (a or b): a. FDA approved use (i or ii): i. In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer; As a single agent for treatment of HER2-overexpressing breast cancer if member has received one or more chemotherapy regimens for metastatic disease; b. Off-label NCCN recommended use (i or ii): i. Men or postmenopausal women, and all the following: a) Disease is ER-positive; b) Herceptin will be used in combination with aromatase inhibition; c) If male, should be receiving concomitant treatment for suppression of testicular steroidogenesis; Both a) and b): a) Disease has one or more of the following characteristics: 1) Hormone receptor-negative; 2) Hormone receptor-positive and endocrine therapy refractory; 3) Concomitant symptomatic visceral disease or visceral crisis; b) Herceptin will be used in one of the following ways: 1) As preferred first-line therapy in combination with pertuzumab with docetaxel or paclitaxel; 2) In combination with docetaxel, vinorelbine, or capecitabine or with paclitaxel with or without carboplatin; Page 2 of 5

3 3) As treatment for trastuzumab-exposed HER2-positive disease in combination with carboplatin, cisplatin, cyclophosphamide, eribulin, gemcitabine, ixabepilone, lapatinib (without cytotoxic therapy), or albumin-bound paclitaxel; 4) In combination with pertuzumab with or without cytotoxic therapy (e.g., vinorelbine or taxane) for one line of therapy beyond first-line therapy in patients previously treated with chemotherapy and trastuzumab in the absence of pertuzumab. C. Metastatic Gastric and Esophageal Adenocarcinomas (must meet 1 or 2): 1. FDA approved use (a, b, and c): a. Diagnosis of HER-2 positive metastatic gastric or gastroesophageal junction adenocarcinoma; b. Herceptin will be administered in combination with cisplatin and capecitabine or 5- fluorouracil; c. Member has not received prior treatment for metastatic disease; 2. Off-label NCCN recommended use (a and b): a. Diagnosis of advanced HER2-neu protein overexpressing esophageal, esophagogastic junction, or gastric adenocarcinoma; b. Herceptin will be used palliative therapy in combination with cisplatin and fluorouracil or capecitabine. D. Central Nervous System Cancer (off-label) (must meet all): 1. Off-label NCCN recommended use (a and b): a. Herceptin will be used as intracerebrospinal fluid (CSF) treatment for leptomeningeal metastases from breast cancer; b. Herceptin will be used in one of the following ways (i, ii, or iii): i. As induction therapy for primary treatment of good-risk patients with normal CSF flow; As maintenance therapy for patients with negative CSF cytology or for clinically stable patients with persistently positive CSF cytology; i As postinduction therapy for patients with positive CSF cytology. E. Other diagnoses/indications 1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) II. Continued Therapy A. All Indications (must meet all): 1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria; 2. Documentation of positive response to therapy, including no disease progression. Approval duration: 12 months B. Other diagnoses/indications (must meet 1 or 2): 1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy. Approval duration: Duration of request or 12 months (whichever is less); or 2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) III. Diagnoses/Indications for which coverage is NOT authorized: Page 3 of 5

4 A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy ERX.PA.01 or evidence of coverage documents IV. Appendices/General Information Appendix A: Abbreviation/Acronym Key FDA: Food and Drug Administration HER2: human epidermal growth factor receptor 2 protein NCCN: National Comprehensive Cancer Network V. Dosage and Administration Indication Dosing Regimen Maximum Dose Breast cancer IV infusion: administer for a total of 52 weeks: Based on weight (adjuvant treatment) As part of a treatment regimen: o Initial dose of 4 mg/kg followed by subsequent doses of 2 mg/kg weekly during chemotherapy for the first 12 weeks (paclitaxel or docetaxel) or 18 weeks (docetaxel/carboplatin) o Subsequent doses of 6 mg/kg every 3 weeks starting one week after the last weekly dose of Herceptin As a single agent: Initial dose of 8 mg/kg followed by subsequent doses of 6 mg/kg every 3 weeks until disease progression Metastatic breast cancer IV infusion: initial dose of 4 mg/kg followed by subsequent doses of 2 mg/kg once weekly until Based on weight Metastatic gastric cancer disease progression IV infusion: initial dose of 8 mg/kg followed by subsequent doses of 6 mg/kg every 3 weeks until disease progression Based on weight VI. VII. Product Availability Multi-dose vial with lyophilized powder: 440 mg References 1. Herceptin Prescribing Information. South San Francisco, CA: Genentech, Inc.; March Available at Accessed May 3, Adjuvant therapy: NCI dictionary of cancer terms. National Cancer Institute at the National Institutes of Health. Available at Accessed May 4, In: National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at NCCN.org. Accessed May 4, Reviews, Revisions, and Approvals Date P&T Approval Date Policy created 05/16 06/16 Increased approval durations from 3/6 months to 6/12 months. Removed non-small cell lung cancer off-label NCCN use as it is a 2B recommendation. 04/17 05/17 Important Reminder Page 4 of 5

5 This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein. Page 5 of 5